For the quarter ending 2026-03-31, CRDF made $41K in revenue. -$12,351K in net income. Net profit margin of -30124.39%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Royalty revenues | 41 | 243 | 120 | 121 |
| Research and development | 6,765 | 5,075 | 8,197 | 11,580 |
| Selling, general and administrative | 6,126 | 2,995 | 3,897 | 3,318 |
| Total operating expenses | 12,891 | 8,070 | 12,094 | 14,898 |
| Loss from operations | -12,850 | -7,827 | -11,974 | -14,777 |
| Interest income | 506 | 612 | 716 | 835 |
| Other income (expense), net | -1 | -1 | 0 | -1 |
| Total other income (expense), net | 505 | 611 | 716 | 834 |
| Net loss | -12,345 | -7,216 | -11,258 | -13,943 |
| Preferred stock dividend payable on series a convertible preferred stock | 6 | 7 | 6 | 6 |
| Net loss attributable to common stockholders | -12,351 | -7,223 | -11,264 | -13,949 |
| Basic EPS | -0.18 | -0.107 | -0.17 | -0.21 |
| Diluted EPS | -0.18 | -0.107 | -0.17 | -0.21 |
| Basic Average Shares | 68,350,000 | 67,435,000 | 66,879,000 | 66,526,000 |
| Diluted Average Shares | 68,350,000 | 67,435,000 | 66,879,000 | 66,526,000 |
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)